These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 16160208)

  • 1. Analytic choices in economic models of treatments for rheumatoid arthritis: What makes a difference?
    Drummond MF; Barbieri M; Wong JB
    Med Decis Making; 2005; 25(5):520-33. PubMed ID: 16160208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden.
    Lekander I; Borgström F; Svarvar P; Ljung T; Carli C; van Vollenhoven RF
    Int J Technol Assess Health Care; 2010 Jan; 26(1):54-61. PubMed ID: 20059781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years.
    Sany J; Cohen JD; Combescure C; Bozonnat MC; Roch-Bras F; Lafon G; Daurès JP
    Rheumatology (Oxford); 2009 Oct; 48(10):1236-41. PubMed ID: 19620209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Not all "quality-adjusted life years" are equal.
    Marra CA; Marion SA; Guh DP; Najafzadeh M; Wolfe F; Esdaile JM; Clarke AE; Gignac MA; Anis AH
    J Clin Epidemiol; 2007 Jun; 60(6):616-24. PubMed ID: 17493521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The comparison of trial data-based and registry data-based cost-effectiveness of infliximab treatment for rheumatoid arthritis in Sweden using a modeling approach.
    Lekander I; Kobelt G; Svarvar P; Ljung T; van Vollenhoven R; Borgström F
    Value Health; 2013; 16(2):251-8. PubMed ID: 23538176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
    Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
    Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative decision analysis modeling in the economic evaluation of tumor necrosis factor inhibitors for rheumatoid arthritis.
    Kamal KM; Miller LA; Kavookjian J; Madhavan S
    Semin Arthritis Rheum; 2006 Aug; 36(1):50-60. PubMed ID: 16887468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
    Lindgren P; Geborek P; Kobelt G
    Int J Technol Assess Health Care; 2009 Apr; 25(2):181-9. PubMed ID: 19331709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The burden of rheumatoid arthritis and access to treatment: health burden and costs.
    Lundkvist J; Kastäng F; Kobelt G
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S49-60. PubMed ID: 18157732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison between integrating clinical practice setting and randomized controlled trial setting into economic evaluation models of therapeutics.
    Farahani P; Levine M; Goeree R
    J Eval Clin Pract; 2006 Aug; 12(4):463-70. PubMed ID: 16907691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.
    van den Hout WB; Goekoop-Ruiterman YP; Allaart CF; de Vries-Bouwstra JK; Hazes JM; Kerstens PJ; van Zeben D; Hulsmans HM; de Jonge-Bok JM; de Sonnaville PB; Dijkmans BA; Breedveld FC
    Arthritis Rheum; 2009 Mar; 61(3):291-9. PubMed ID: 19248130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada.
    Kobelt G; Andlin-Sobocki P; Maksymowych WP
    J Rheumatol; 2006 Apr; 33(4):732-40. PubMed ID: 16583476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
    DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F
    Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in economic evaluation of new drugs: experience with rituximab in Hungary.
    Brodszky V; Orlewska E; Pentek M; Karpati K; Skoupa J; Gulacsi L
    Med Sci Monit; 2010 Jan; 16(1):SR1-5. PubMed ID: 20037504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Sheffield rheumatoid arthritis health economic model.
    Tosh J; Brennan A; Wailoo A; Bansback N
    Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv26-31. PubMed ID: 21859702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of the determination of autoantibodies against cyclic citrullinated peptide in the early diagnosis of rheumatoid arthritis.
    Konnopka A; Conrad K; Baerwald C; König HH
    Ann Rheum Dis; 2008 Oct; 67(10):1399-405. PubMed ID: 18192304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping from the Health Assessment Questionnaire to the EQ-5D: the impact of different algorithms on cost-effectiveness results.
    Pennington B; Davis S
    Value Health; 2014 Dec; 17(8):762-71. PubMed ID: 25498771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analyses of targeted immunomodulators in rheumatoid arthritis: systematic review.
    Sussman M; Tao C; Patel P; Tundia N; Clewell J; Menzin J
    J Med Econ; 2020 Jun; 23(6):610-623. PubMed ID: 31971039
    [No Abstract]   [Full Text] [Related]  

  • 20. A clinician's critique of rheumatoid arthritis health economic models.
    Jobanputra P
    Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv48-iv52. PubMed ID: 21859706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.